Ishani Maharaj of Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
News|Articles|May 2, 2005
- Pharmaceutical Technology-05-02-2005
- Volume 29
- Issue 5
High Molecular Weight Polyethylene Oxide-Based Drug Delivery Systems - Part I: Hydrogels and Hydrophilic Matrix Systems
The authors review the solution and powder properties of polyethylene oxide and its various applications in hydrogels and hydrophilic matrix systems.
Advertisement
Articles in this issue
over 21 years ago
New Vaccine Technologies Carry and Deliver by Kaylynn Chiarelloover 21 years ago
GenerationNextover 21 years ago
New Vaccine Technologies Carry and Deliverover 21 years ago
May 2005over 21 years ago
Bar Coding Deadline Loomsover 21 years ago
In the Spotlight - May 2005over 21 years ago
New FDA Policies Shape Pharma Development and Productionover 21 years ago
Automating HPLC and GC Analytical Method Validationover 21 years ago
Price MattersAdvertisement
Related to this article
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
The FDA’s Rare Disease Framework Initiative brings risk-based CMC review and pre-approval inspections into scope for sponsors, CDMOs, and quality teams.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Rare Disease Framework Puts CMC Review in Scope
2
Rare Pediatric PRVs: Manufacturing Strategies for Expedited Approval, Part 1
3
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
4
PharmTech AI Pulse Check: AI Watermark Vulnerability
5